Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis.
about
Epicure: a European epidemiological study of patients with an advanced or metastatic Urothelial Carcinoma (UC) having progressed to a platinum-based chemotherapySEOM Clinical Guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2016).Effectiveness of capecitabine with or without docetaxel therapy for the treatment of patients with advanced urothelial carcinoma: a single-institution experienceThe Emerging Role of PD-1/PD-L1-Targeting Immunotherapy in the Treatment of Metastatic Urothelial Carcinoma.PD-1 and PD-L1 antibodies in cancer: current status and future directions.Nivolumab for the treatment of bladder cancer.Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.Biomarkers for immunotherapy in bladder cancer: a moving target.Anti-Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development.Association of an aurora kinase a (AURKA) gene polymorphism with progression-free survival in patients with advanced urothelial carcinoma treated with the selective aurora kinase a inhibitor alisertib.Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study.
P2860
Q36143699-35445AF6-F298-4B74-B35C-C5096E288D31Q37475193-CFBAAFA6-9786-44CC-8772-F1DC2B87274DQ37665453-1303FC98-B1E8-47E5-B61F-1C482158CC6BQ38612965-CFB5F3F0-DC61-4C5B-9ACC-9D733F7EE06AQ38755931-63D22438-4C73-4465-B1A1-8FDF81C0B222Q39454030-8A7544FF-E4EF-4087-956B-DB22AC642B5CQ41979947-4FC261F2-66C0-497E-9236-E871D4A98F1BQ47382727-617E6AE9-C764-441F-B5BB-F138D1FC9C59Q47737204-339FACDC-DF62-45FA-8E86-3E81F702644FQ48281115-90C1EF6B-58BA-4E6F-A127-D61CCC3B86A9Q49821320-FD7F4768-C429-4106-B7F6-D6766D829486
P2860
Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Second-line single-agent versu ...... atic review and meta-analysis.
@en
type
label
Second-line single-agent versu ...... atic review and meta-analysis.
@en
prefLabel
Second-line single-agent versu ...... atic review and meta-analysis.
@en
P2093
P2860
P50
P356
P1433
P1476
Second-line single-agent versu ...... matic review and meta-analysis
@en
P2093
G Sonpavde
J Bellmunt
M D Galsky
P Giannatempo
P2860
P356
10.1093/ANNONC/MDV509
P577
2015-10-20T00:00:00Z